



THE POWER OF PURPOSE IN EMPLOYEE RETENTION

In the wake of the tumultuous year that was 2020, organizations are reevaluating their approach to employee well-being, purpose, and resilience, while employees themselves are questioning if their companies provide them with these crucial elements - a shift that has profound implications for talent management and business success.

Almost two-thirds of US-based employees surveyed acknowledged that COVID-19 had led them to contemplate their life's purpose. Nearly half of them admitted to reconsidering the type of work they engage in due to the pandemic. Continue reading [here](#).

TABLE OF CONTENTS

Professional Identity and Medicines Development • P. 2

Conversations with the Academy:
The Growing Relevance of RWE Studies • P. 3

The Fight against Cancer recording available • P. 4

2024 applications for CMD program now open • P. 4

Large-scale study on early detection of cancer • P. 5

Resource reminder: monthly EMA newsletter • P. 5

PROFESSIONAL IDENTITY AND MEDICINES DEVELOPMENT

Reflections from Academy Alumna: Ho-Jin Lee



HO-JIN LEE

“Professionals working in the pharma industry are required to build and develop enduring relationships and collaborations with academia, medical societies, patient advocacy groups, healthcare systems, and even governments and payers all over the world. Since professionals should gather insights from various stakeholders and identify unmet needs, it is important to advance a powerful Professional Identity that enables an individual to enhance competence and be confident about his/her job, career, and profession, and also enables him/her to have a strong sense of purpose, resulting in ultimately improving patients’ outcomes. In order to do so, well-organized need-based continuous educational training that gives insights into skills that would be useful in Medicines Development, as well as cutting-edge scientific subject matter including disease, diagnosis, management, treatment, and relevant knowledge, are prime examples.

Professionals involved in Medicines Development may have diverse professional identities and a sense of purpose depending on their professions and stages of the life cycle of drugs. Medicines Development experts with expertise in certain therapeutic areas are especially required to exchange scientific insights with customers and understand unmet medical needs to maximize the value of a drug throughout its entire life cycle.” **[Read her complete essay here.](#)**

Ho-Jin Lee is a Senior Medical Manager in Internal Medicine at Pfizer Korea, Seoul, South Korea. She holds a Bachelor of Science in Pharmacy (BSPHarm) from Seoul National University, as well as a Master of Public Health in Healthcare Management and Policy (MPH) from the same institution. Before joining Pfizer, she worked in Medical Affairs and Marketing at a global pharmaceutical company, in addition to her clinical role as a pharmacist at a university hospital. She is a graduate of the Academy’s 2022 cohort.



Conversations with the Academy

Presents:

"The Growing Relevance of RWE Studies"

October 30, 2023
9:00AM to 10:00AM EST



Laura Fabbri, PhD
Head of Real World Evidence
Chiesi Pharmaceutical
Parma, Italy



Sreeram Ramagopalan, PhD, MBA
Principal and Market Access
and Payer Evidence Lead
Lane Clark & Peacock
London, England

1

Real World Evidence (RWE) studies are gaining more clinical importance, as pharma companies, Investigators and Regulatory agencies seek improved knowledge of the benefit/risk ratio of a new medicine when it is used in normal conditions. Indeed, regulators are so interested in them, that they are pleased to see them as part of the NDA dossier. This captivating webinar with Laura Fabbri, PhD and Sreeram Ramagopalan, PhD, MBA, explores the evolving landscape of RWE and highlights its pivotal role in drug development.

Learning Objectives

- 1. Understand the clinical and regulatory importance of RWE studies.**
- 2. Appreciate how RWE studies can also be useful in the HTA preparation.**
- 3. Comment on the real approach a company is planning in implementing these studies.**

[Register Now](#)

‘THE FIGHT AGAINST CANCER- VACCINES OR IMMUNOTHERAPEUTICS?’ RECORDING NOW AVAILABLE

In this webinar, held on September 25, 2023, Dr. Otfried Kistner and Professor Gilberto Filaci provided an in-depth discussion of the most promising approaches to cancer treatment currently being explored in the field.

Together, they led an engaging discussion to present an up-to-date overview of ongoing research endeavors focused on the development and discovery of a cancer vaccine, discuss the current status of ongoing investigations in the field, and evaluate the merits and limitations inherent in current research initiatives.



Our sincere appreciation for our expert faculty, and we remain motivated by the active audience participation.

Missed this informative event? You can access the recorded version by clicking [here](#).

APPLICATIONS NOW AVAILABLE FOR WORLD-CLASS EDUCATION IN MEDICINES DEVELOPMENT

The GMDP Academy, in collaboration with King's College London, is pleased to accept applications for the 2024 cohort of the highly acclaimed Certification in Medicines Development (CMD) program.

Don't miss your chance to become part of a truly unique educational journey in Medicines Development! Join fellow professionals from around the world and advance your career with the 2024 GMDP Academy-King's College London Certification in Medicines Development Program .

Group rates are available for sponsoring organizations. For more information contact admissions@gmdpacademy.org.

[Apply Today](#)

LARGE-SCALE STUDY ON EARLY CANCER DETECTION IN SYMPTOMATIC PATIENTS IN ENGLAND AND WALES

A recent study published in The Lancet Oncology sought to assess the effectiveness of a methylation-based multicancer early detection (MCED) diagnostic test in symptomatic patients referred from primary care as a means to stratify cancer risk by analyzing circulating tumor DNA.

Conducted at various National Health Service (NHS) hospital sites in England and Wales, this multicenter prospective observational study included participants aged 18 and above who were referred with non-specific symptoms or symptoms possibly related to gynecological, lung, or upper/lower gastrointestinal cancers.



Participants provided blood samples during their urgent investigations. Continue reading [here](#).²

RESOURCE REMINDER: EMA NEWSLETTERS



We extend a friendly reminder of this invaluable resource, the monthly EMA newsletter. By subscribing to the EMA newsletter, you receive key information relating to medicines for human use. This edition features decisions made by scientific committees as well as updates on medicines safety.

Click [here](#) to access the most up-to-date newsletter from EMA.

REFERENCES

1. Dhingra, N., Samo, A., Schaninger, B., & Schrimper, M. (2021). Help your employees find purpose—or watch them leave. McKinsey & Company. <https://www.mckinsey.com/capabilities/people-and-organizational-performance/our-insights/help-your-employees-find-purpose-or-watch-them-leave>
2. Nicholson, B. D., Oke, J., Virdee, P. S., Harris, D., O'Doherty, C., Park, J., Hamady, Z., Sehgal, V., Millar, A., Medley, L., Tonner, S., Vargova, M., Engonidou, L., Riahi, K., Liu, Y., Hiom, S., Kumar, H., Nandani, H., Kurtzman, K. N., . . . Middleton, M. R. (2023). Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY): a large-scale, observational cohort study. *Lancet Oncology*, 24(7), 733–743. [https://doi.org/10.1016/s1470-2045\(23\)00277-2](https://doi.org/10.1016/s1470-2045(23)00277-2)

Thanks for reading!

The GMDP Academy Newsletter is published twice monthly and is compiled by the following:

Medical Editor: Domenico Criscuolo

Media Manager: Whitney English

Editorial Board: Pravin Chopra, Jacob Coats, Honorio Silva, Peter Stonier

Operations Office: Amanda Schmitt, Gustavo Silva, Kit Vale

CONTACT US:



420 Lexington Ave. Ste. 300
New York, NY 10170

(332) 333-2438